ArticleOncotarget2018

Molecular responses to therapeutic proteasome inhibitors in multiple myeloma patients are donor-, cell type- and drug-dependent.

Eleni-Dimitra Papanagnou et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.